Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145481 | 0.92 | SMN1; SMN2 (0.56) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL2145310 | 0.91 | MAPT (0.57) | KMT2AMAPTMEN1TRPV1NPC1 | |
| SCHEMBL2145497 | 0.88 | RAB9A (0.49) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL2145806 | 0.87 | CA12 (0.52) | KMT2AMAPTMEN1SMN1; SMN2RECQL | |
| SCHEMBL2145359 | 0.86 | MEN1 (0.44) | KMT2AMEN1GAACA12CA2 | |
| SCHEMBL2145243 | 0.83 | SAE1 (0.52) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL2145716 | 0.83 | GHSR (0.42) | MAPTNPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL13651666 | 0.82 | KMT2A (0.46) | KMT2AGAAALDH1A1 | |
| SCHEMBL2145641 | 0.82 | RAB9A (0.46) | KMT2AMAPTMEN1CASP3SENP7 | |
| SCHEMBL2145865 | 0.82 | MEN1 (0.43) | KMT2AMAPTMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329738-B2 | Use of AMPK-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-12-11 | — | — | US | claimed |
| EP-2040702-B1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | claimed |
| EP-2040702-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Merck Patent GmbH (DE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008006432-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2008-01-17 | — | — | WO | claimed |
| US-8329738-B2 | Use of AMPK-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-12-11 | — | — | US | disclosed |
| EP-2040702-B1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| EP-2040702-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Merck Patent GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006432-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253764-A1 | USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PRKAG1, PRKAB1, PRKAG2 | KMT2A 2324/4885MAPT 3516/4885MEN1 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.